WO2010077364A3 - Stroke-generated angiogenesis enhancers and uses thereof - Google Patents
Stroke-generated angiogenesis enhancers and uses thereof Download PDFInfo
- Publication number
- WO2010077364A3 WO2010077364A3 PCT/US2009/006758 US2009006758W WO2010077364A3 WO 2010077364 A3 WO2010077364 A3 WO 2010077364A3 US 2009006758 W US2009006758 W US 2009006758W WO 2010077364 A3 WO2010077364 A3 WO 2010077364A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stroke
- generated
- angiogenesis
- stimulating
- enhancing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2011007108A MX2011007108A (en) | 2008-12-31 | 2009-12-31 | Stroke-generated angiogenesis enhancers and uses thereof. |
BRPI0924061A BRPI0924061B8 (en) | 2008-12-31 | 2009-12-31 | pharmaceutical composition comprising an endorepellin protein |
RU2011131772/15A RU2011131772A (en) | 2008-12-31 | 2009-12-31 | ANGIOGENESIS AMPLIFIERS AS A RESULT OF STROKE AND THEIR APPLICATION |
CA2748811A CA2748811C (en) | 2008-12-31 | 2009-12-31 | Endorepellin fragments and uses thereof for the treatment of stroke |
ES09798982.6T ES2524366T3 (en) | 2008-12-31 | 2009-12-31 | Enhancers of angiogenesis generated by stroke and their uses |
CN2009801575925A CN102355905A (en) | 2008-12-31 | 2009-12-31 | Stroke-generated angiogenesis enhancers and uses thereof |
AU2009333815A AU2009333815B2 (en) | 2008-12-31 | 2009-12-31 | Stroke-generated angiogenesis enhancers and uses thereof |
EP09798982.6A EP2373328B1 (en) | 2008-12-31 | 2009-12-31 | Stroke-generated angiogenesis enhancers and uses thereof |
JP2011544419A JP5591825B2 (en) | 2008-12-31 | 2009-12-31 | Enhancer of angiogenesis caused by stroke and use thereof |
KR1020117017783A KR101746749B1 (en) | 2008-12-31 | 2009-12-31 | Stroke-generated angiogenesis enhancers and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20406408P | 2008-12-31 | 2008-12-31 | |
US61/204,064 | 2008-12-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010077364A2 WO2010077364A2 (en) | 2010-07-08 |
WO2010077364A3 true WO2010077364A3 (en) | 2010-10-21 |
Family
ID=42174116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/006758 WO2010077364A2 (en) | 2008-12-31 | 2009-12-31 | Stroke-generated angiogenesis enhancers and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US8466105B2 (en) |
EP (1) | EP2373328B1 (en) |
JP (1) | JP5591825B2 (en) |
KR (1) | KR101746749B1 (en) |
CN (2) | CN102355905A (en) |
AU (1) | AU2009333815B2 (en) |
BR (1) | BRPI0924061B8 (en) |
CA (1) | CA2748811C (en) |
ES (1) | ES2524366T3 (en) |
MX (1) | MX2011007108A (en) |
RU (1) | RU2011131772A (en) |
WO (1) | WO2010077364A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9358273B2 (en) | 2010-01-06 | 2016-06-07 | The Texas A&M University System | Use of perlecan domain V in treating amyloidogenic disease |
US9072713B2 (en) | 2010-07-01 | 2015-07-07 | The Texas A&M University System | Perlecan domain V protects, repairs and restores ischemic brain stroke injury and motor function |
WO2019118689A1 (en) * | 2017-12-13 | 2019-06-20 | University Of Kentucky Research Foundation | Compositions and methods for enhancing neuro-repair |
CN108715833B (en) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | Preparation method of microsphere loaded with platelet lysate |
US20230293632A1 (en) * | 2020-07-24 | 2023-09-21 | Stream Biomedical, Inc. | Use of perlecan and fragments thereof to reduce the risk of death in stroke patients |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003048333A2 (en) * | 2001-12-04 | 2003-06-12 | Thomas Jefferson University | Endorepellin compositions and methods for inhibiting angiogenesis |
-
2009
- 2009-12-31 CN CN2009801575925A patent/CN102355905A/en active Pending
- 2009-12-31 CN CN201410468572.2A patent/CN104208659A/en active Pending
- 2009-12-31 WO PCT/US2009/006758 patent/WO2010077364A2/en active Application Filing
- 2009-12-31 KR KR1020117017783A patent/KR101746749B1/en active IP Right Grant
- 2009-12-31 US US12/655,503 patent/US8466105B2/en active Active
- 2009-12-31 MX MX2011007108A patent/MX2011007108A/en active IP Right Grant
- 2009-12-31 AU AU2009333815A patent/AU2009333815B2/en active Active
- 2009-12-31 BR BRPI0924061A patent/BRPI0924061B8/en active IP Right Grant
- 2009-12-31 JP JP2011544419A patent/JP5591825B2/en active Active
- 2009-12-31 CA CA2748811A patent/CA2748811C/en active Active
- 2009-12-31 RU RU2011131772/15A patent/RU2011131772A/en unknown
- 2009-12-31 EP EP09798982.6A patent/EP2373328B1/en active Active
- 2009-12-31 ES ES09798982.6T patent/ES2524366T3/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003048333A2 (en) * | 2001-12-04 | 2003-06-12 | Thomas Jefferson University | Endorepellin compositions and methods for inhibiting angiogenesis |
Non-Patent Citations (4)
Title |
---|
CLARKE D ET AL: "Endorepellin and endostatin affect the neurovascular unit in vitro.", J.NEUROCHEM. (104, SUPPL. 1, 77, 2008) 0 REF. CODEN: JONRA9 ISSN: 0022-3042 AV - TEXAS A&M UNIV, COLL MED, COLLEGE STN, TX, USA, 77843., 2008, XP009134063 * |
HANKEY ET AL: "Statins after transient ischaemic attack and ischaemic stroke", LANCET NEUROLOGY, LANCET PUBLISHING GROUP, LONDON, GB LNKD- DOI:10.1016/S1474-4422(06)70559-2, vol. 5, no. 10, 1 October 2006 (2006-10-01), pages 810 - 812, XP024969106, ISSN: 1474-4422, [retrieved on 20061001] * |
MONGIAT M ET AL: "Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.M210445200, vol. 278, no. 6, 7 February 2003 (2003-02-07), pages 4238 - 4249, XP002547225, ISSN: 0021-9258, [retrieved on 20021114] * |
O'REGAN ET AL: "Statin Therapy in Stroke Prevention: A Meta-analysis Involving 121,000 Patients", AMERICAN JOURNAL OF MEDICINE, EXCERPTA MEDICA, INC, UNITED STATES LNKD- DOI:10.1016/J.AMJMED.2007.06.033, vol. 121, no. 1, 8 January 2008 (2008-01-08), pages 24 - 33, XP022458762, ISSN: 0002-9343 * |
Also Published As
Publication number | Publication date |
---|---|
JP5591825B2 (en) | 2014-09-17 |
AU2009333815B2 (en) | 2016-02-18 |
US20100168025A1 (en) | 2010-07-01 |
ES2524366T3 (en) | 2014-12-05 |
JP2012514036A (en) | 2012-06-21 |
US8466105B2 (en) | 2013-06-18 |
AU2009333815A1 (en) | 2011-08-11 |
KR101746749B1 (en) | 2017-06-13 |
MX2011007108A (en) | 2011-09-28 |
EP2373328B1 (en) | 2014-08-20 |
CN102355905A (en) | 2012-02-15 |
CN104208659A (en) | 2014-12-17 |
WO2010077364A2 (en) | 2010-07-08 |
BRPI0924061A2 (en) | 2015-07-07 |
EP2373328A2 (en) | 2011-10-12 |
RU2011131772A (en) | 2013-02-10 |
CA2748811C (en) | 2019-07-16 |
CA2748811A1 (en) | 2010-07-08 |
BRPI0924061B1 (en) | 2020-11-24 |
KR20110127131A (en) | 2011-11-24 |
BRPI0924061B8 (en) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500644A1 (en) | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections | |
PH12017501461A1 (en) | Antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
WO2006116731A3 (en) | Personal care compositions comprising a dipeptide | |
BR112012017054A2 (en) | "oxintomodulin peptide analog, its use as well as pharmaceutical composition" | |
WO2008083239A3 (en) | Compositions and methods for stimulating an immune response | |
WO2009060281A3 (en) | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties | |
WO2012112690A3 (en) | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains | |
PE20160653A1 (en) | IL-17 BINDING PROTEINS | |
BR112012018386A8 (en) | "phosphatidylinositol 3-kinase isoindolinone inhibitors" | |
WO2010111018A8 (en) | Antibody drug conjugates (adc) that bind to 24p4c12 proteins | |
EP2390265A3 (en) | Insulinotropic peptide derivative wherein its N-terminal amino acid is modified | |
NZ602471A (en) | Antagonists of activin-actriia and uses for increasing red blood cell levels | |
NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
BR112013026706A2 (en) | nutritional compositions comprising alpha hydroxy isocaproic acid | |
EA200971107A1 (en) | CATECHOLAMINE DERIVATIVES, USEFUL FOR THE TREATMENT OF PARKINSON'S Disease | |
UA99094C2 (en) | Method for the treatment of patients with autoantibody positive disease | |
BR112012019924A2 (en) | dr5 agonist binding polypeptides. | |
WO2010077364A3 (en) | Stroke-generated angiogenesis enhancers and uses thereof | |
WO2009062576A3 (en) | Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | |
EA201070195A1 (en) | DERIVATIVES 1,2,3,4-TETRAGIDROPYRROLO [1,2-A] PIRAZIN-6-CARBOXAMIDES AND 2,3,4,5-TETRAHYDROPYRROLO [1,2-a] [1,4] -DIAZEPIN-7-CARBOXAMIDES , THEIR RECEIVING AND THEIR APPLICATION IN THERAPY | |
WO2008113770A3 (en) | Anti-androgen peptides and uses thereof in cancer therapy | |
WO2010012940A3 (en) | Microparticulate oral drug form useful for the modified release of nanoparticles | |
WO2010052243A3 (en) | Neurotensin-derived branched peptides and uses thereof | |
EP4218786A3 (en) | Opiorphin for use as analgesic agent | |
WO2007095609A3 (en) | Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980157592.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09798982 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2011544419 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2748811 Country of ref document: CA Ref document number: MX/A/2011/007108 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009798982 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009333815 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20117017783 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011131772 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2009333815 Country of ref document: AU Date of ref document: 20091231 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0924061 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI0924061 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110630 |